Citation Impact
Citing Papers
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1998
Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer
2001
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
2001
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
2004 Standout
Correlation between p53, c-erbB-2, and topoisomerase II? expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications
1999
Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients
2000
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
2002
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
1994
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1995
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
2003
Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
2010 StandoutNobel
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
1997
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
2005
Cisplatin nephrotoxicity
1989
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Anthrazykline in der Krebstherapie
1997 Standout
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Stress response inhibits the nephrotoxicity of cisplatin
2004
Cisplatin Nephrotoxicity: A Review
2007 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function
1995
Block copolymer micelles for drug delivery: design, characterization and biological significance
2001 Standout
CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases
2011 StandoutNobel
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-δ7-prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826)
2001 StandoutNobel
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
2012
Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer
1993
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
The Ki-67 protein: From the known and the unknown
2000 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Anticancer Drug???Induced Kidney Disorders
2001
Breast cancer metastasis: markers and models
2005 Standout
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study
2006
Cisplatin nephrotoxicity
2003 Standout
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells.
1989
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment
2013 Standout
Biochemical Markers of the Progress of Differentiation in Cloned Teratocarcinoma Cell Lines
1977 StandoutNobel
Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102
2005
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases
1986 Standout
Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
2001
Benign Neoplasms of the Larynx
1984
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
The Anthracycline Antineoplastic Drugs
1981 Standout
SERUM-ALPHA1-FETOPROTEIN IN PATIENTS WITH TESTICULAR TUMOURS
1976
Condyloma in Pregnancy Is Strongly Predictive of Juvenile-Onset Recurrent Respiratory Papillomatosis
2003 Standout
Chemotherapy of advanced soft-tissue sarcomas in adults
1977
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
2003
Tissue microarrays for gene amplification surveys in many different tumor types.
1999
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
2015 Standout
Works of J Guerrin being referenced
Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated withcis-diamminedichloroplatinum(II)
1990
Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
1996
Loss of heterozygosity at theTP53 gene: Independent occurrence from genetic instability events in node-negative breast cancer
1997
[Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
1994
An Uncommon Apudoma: A Functional Chemodectoma of the Larynx: Report of a Case and Review of the Literature
1980
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
1986
Cisplatinumdiamminodichloride (CPDD) in Chemotherapy of Cancers: A Phase II Therapeutic Trial
1980
Urinary β2-microglobulin early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide
1986
[Prognostic value of CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV].
1996
Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy.
1995
[Practical value of alpha fetoprotein in the diagnosis and postoperative surveillance of embryonic tumors of the testis].
1971
Chemotherapy of advanced breast cancer
1978
p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer
1997
[Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
1982
[Anticancerous chemotherapy trial with duborimycin. Analysis of 151 cases].
1977